Press

Filament Health Appoints New Members To Board Of Directors And Advisory Council

Aug 26 • 3 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical‐stage natural psychedelic drug development company, today announced the appointment of Dr. Konstantin Adamsky of Negev Capital to its Board of Directors, and Jeff Chilton of Nammex to the Company’s Advisory Council. Konstantin Adamsky, PhD, is the Chief Operating Officer of Negev Capital, a psychedelic medical intervention investment fund that has made…

PharmaDrug Advances Psychedelics Pharmaceutical Program Focused on DMT and DMT Analogues

Aug 26 • 7 min read

PharmaDrug Inc. (CSE: PHRX | OTCQB: LMLLF), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company continues to successfully execute on key objectives related to its multiprong psychedelics research and development strategy by generating potential shareholder value through a…

Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program

Aug 26 • 3 min read

Awakn Life Sciences Corp. (NEO: AWKN | OTCQB: AWKNF | FSE: 954), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today it has signed a twelve month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license…

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.

Aug 26 • 3 min read

SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (CSE:…

PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Aug 26 • 5 min read

PSYC Corporation (OTCPink: PSYC), a multimedia leader focused on the emerging psychedelic and cannabis sectors, is proud to announce the Company, in partnership with Digital Acorn Ltd., continues to progress with the development of its Bonfire project (f/k/a “PsycheDev”). The companies, through Psychedelic Spotlight, will host their second virtual community-wide event on August 29, 2022,…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435